Levi Van Hijfte

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target.

Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target.

Journal: Neuro-oncology advances
Published: January 13, 2026

TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.

TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.

Journal: Cell reports. Medicine
Published: September 09, 2025

T cell immunity in glioma and potential implications for immunotherapy: a systematic review.

T cell immunity in glioma and potential implications for immunotherapy: a systematic review.

Journal: Neuro-oncology
Published: July 01, 2025

T cell immunity in glioma and potential implications for immunotherapy: A systematic review.

T cell immunity in glioma and potential implications for immunotherapy: A systematic review.

Journal: Neuro-oncology
Published: July 01, 2025

YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas.

YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas.

Journal: Neuro-oncology
Published: May 20, 2025

YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas.

YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas.

Journal: Neuro-oncology
Published: May 20, 2025

Targeting CHEK2-YBX1&YBX3 regulatory hub to potentiate immune checkpoint blockade response in gliomas.

Targeting CHEK2-YBX1&YBX3 regulatory hub to potentiate immune checkpoint blockade response in gliomas.

Journal: bioRxiv : the preprint server for biology
Published: March 31, 2025

Transcriptomic analysis of EGFR co-expression and activation in glioblastoma reveals associations with its ligands.

Transcriptomic analysis of EGFR co-expression and activation in glioblastoma reveals associations with its ligands.

Journal: Neuro-oncology advances
Published: February 17, 2025

Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.

Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.

Journal: Acta neuropathologica
Published: June 06, 2024

Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytoma.

Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytoma.

Journal: Nature communications
Published: April 29, 2024

Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.

Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.

Journal: bioRxiv : the preprint server for biology
Published: April 02, 2024

Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling.

Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling.

Journal: Nature cancer
Published: February 28, 2024
Showing 1-12 of 15

Last Updated: 09/26/2026